December 15
CPMP Recommends Approval in Europe for Visudyne™ Therapy in the Treatment of Pathologic Myopia
PDF version
December 14
QLT Issues Financial Update On Sales Outlook For Q4 2000
December 12
Business Week Selects Visudyne™ Therapy as One of the 'Best Products of 2000'
November 10
Health Care Financing Administration Issues National Coverage Policy for Visudyne™ Therapy
November 9
Drug That Treats Leading Cause of Blindness Wins Popular Science Award
October 31
QLT Announces Positive Skin Cancer Results
October 17
QLT Announces Third Quarter Financial Results
October 11
QLT Announces Visudyne™ Sales for Third Quarter
October 3
Visudyne™ Supplemental Filing Submitted to European Union Health Authorities by QLT and CIBA Vision
September 29
QLT CEO Named Entrepreneur Of The Year, Pacific Region
September 6
QLT Announces Senior Management Changes
August 29
Visudyne™ Supplemental Filing Granted Priority Review by FDA
August 14
QLT and CIBA Vision Seek to Expand the Indication for Visudyne™
August 1
QLT Announces Financial Results for Second Quarter and First Half of 2000
July 28
EU Commission Approves Visudyne™ for the Treatment of Wet AMD in the European Union
July 11
QLT Appoints Vice President, Project Management
June 30
QLT Files Counterclaim On Intellectual Property Suit
June 9
QLT Announces Completion Of Sale Of PHOTOFRIN� Rights To Axcan
June 1
Health Canada Approves Breakthrough Therapy for Devastating Eye Disease
May 8
Health Canada Grants Special Access Program For Visudyne™ Therapy
May 5
QLT Announces First Quarter Results
QLT Annual General Meeting Held in Vancouver
May 3
Visudyne™ Data Highlighted At The Association For Research In Vision And Opthalmology Annual Conference
May 1
QLT to Sell PHOTOFRIN� Rights to Axcan
April 27
QLT Announces Intellectual Property Suit
April 1
CIBA Vision and QLT to Expand Strategic Alliance
April 13
CPMP Recommends Approval in Europe for Visudyne™ Therapy in the Treatment of Wet AMD
April 12
FDA Approves Visudyne™ Therapy for AMD
March 28
QLT and CIBA Vision Announce Positive Visudyne™ Clinical Results
March 15
Treatment-Investigational New Drug Program for Visudyne™ Therapy for Wet AMD to Expand in North America
March 10
QLT Announces Senior Executive Appointments
March 1
QLT Announces Fourth Quarter and 1999 Year-end Results
February 11
FDA Takes Positive Action as Visudyne™ Review Nears Completion
January 11
Sanofi-Synthelabo Inc. to Convert QLT Preference Shares
